Managing cGvHD is a journey that requires ongoing support.
This site helps you understand your condition and explore your treatment.
This website is intended for patients aged 12 years and older with chronic graft-versus-host disease (chronic GVHD) who have received at least two prior lines of systemic therapy and have been prescribed Rezurock (belumosudil) residing in the United Kingdom.
Where would you like to begin?
Explore your treatment further and find support for cGvHD
MAT-XU-2303463 (v3.0)
Date of Preparation: September 2026
|
Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Ye low Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple app Store. Alternatively, you can report side effects to Sanofi on Tel: 0800 0902 314 or send via email to UK-drugsafety@sanofi.com By reporting side effects, you can help provide more information on the safety of this medicine. ▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects that you may get. See www.mhra.gov.uk/yellowcard for how to report side effects. |
